Processa Pharmaceuticals Will Be Evaluating HT-100 As Treatment For IPF
Senior Director of Multichannel Content for Pulmonary Fibrosis News, Michael Morale, discusses how Processa Pharmaceuticals will evaluate HT-100 as a treatment for IPF and other fibrotic diseases.
Are you interested in learning more about Pulmonary Fibrosis? If so, please visit pulmonaryfibrosisnews.com/
What do you think about this news? Listen to this flash briefing episode and share your thoughts in the comment section below!
Sorry, there were no replies found.
Log in to reply.